I’ve spent 20+ years validating static systems.
Now I’m watching real-time analytics platforms make decisions faster than we can explain, justify, or defend them.
That should make every GxP leader pause
AI in pharma just crossed a quiet line.
Not in production. Not in pilots.
But inside regulatory sandboxes designed to test what should be allowed next.
One robot arm. One sterile isolator. Zero human intervention.
The twist? The AI deciding what happens in Grade A hasn’t actually been approved—or deployed—yet.
90% of pharma AI pilots never scale. I’ve seen the pattern—and it’s not data or models. It’s the absence of explainable AI when regulators start asking questions.
We’re building machines to think faster than us.
Yet discovery still begins with human uncertainty.
One robot can replace 8 operators — but if it fails, it can invalidate 80,000 doses in seconds.
In pharma manufacturing, robots aren’t just machines anymore. They’re regulated GxP systems.
